secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2024-01-04T23:59:59+00:00
Accession:  0000950170-24-001490
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet Bio gets FDA IND clearance for ADI-001 in lupus nephritis; plans Phase 1 in Q2 2024
--------------------------------------------------------------------------------

- FDA cleared IND for ADI-001 in lupus nephritis Dec 2023; Phase 1 start planned Q2 2024.
- Focusing ADI-001 Phase 1 GLEAN enrollment on MCL patients; June 2023 data showed 80% CR rate.
- ADI-001 clinical update expected 2H 2024; evaluating accelerated approval pathway for MCL.
- ADI-270 IND submission for renal cell carcinoma planned Q2 2024 after positive pre-IND meeting.
- Cash and equivalents expected to fund operations into second half of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024001490/0000950170-24-001490-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000095017024001490/acet-20240104.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-001490

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer